Cannabinoids in the spotlight: DSM and Brains Bioceutical partner to support early-stage cannabinoid-based drug development
30 Jun 2021 | 4 min
The science behind cannabidiol (CBD) is growing rapidly – a new and exciting field of research with promising findings in a wide variety of health areas including CNS (central nervous system) diseases, pain disorders, cancer and more. This is creating a myriad of opportunities to expand treatment strategies and support global patient health through the development of bespoke CBD-based drug products.
Download our NEW brochure to unlock the potential of CBD-based innovation.
Tune in to our new expert-led webinar series, brought to you in partnership with Brains Bioceutical, to discover the latest and greatest science surrounding cannabidiol in medical use. Joined by Dr. David (Dedi) Meiri, Associate Professor at the Faculty of Biology at the Technion and a member of the Technion Integrated Cancer Center (TICC), and Renata Heusser Jungman, President of the Swiss Dravet-Syndrome Association, the first session explores the fast-evolving research on the endocannabinoid system and its practical applications for disease treatment.
The CBD market is full of promise, but it takes more than ingredients to enter the CBD market with confidence. It takes a partner.
Together with Brains Bioceutical – a pioneer in the CBD API market – we’re helping our customers explore the potential of CBD-based pharmaceuticals. Our newly launched innovation platform enables agile, early-stage drug development to deliver value-added CBD-based products in a rapidly evolving market. We have the core competencies, combined with a deep understanding of patient and customer needs, to help brands enter the CBD market with confidence. With more than 70 years of experience in producing and securing the supply of APIs, we bring passion, unique innovation expertise and support in managing the market entry registration process.
Together, let’s deliver CBD-based pharmaceuticals with purpose. Connect with one of our experts today.
30 Jun 2021 | 4 min